Rendering

Component: (Network and Table)
Network
30703 - Disclosure - STOCK-BASED COMPENSATION (Tables)
(http://www.BioPharmX.com/role/DisclosureStockBasedCompensationTables)
Table(Implied)
Slicers (applies to each fact value in each table cell)
Reporting Entity [Axis]0001504167 (http://www.sec.gov/CIK)
STOCK-BASED COMPENSATIONPeriod [Axis]
2015-02-01 - 2016-01-31
STOCK-BASED COMPENSATION
 
Summary of stock based compensation expense

        The following table summarizes the stock-based compensation expenses included in the Company's Statement of Operations and Comprehensive Loss for the periods ended (in thousands):

                                                                                                                                                                                    

 

 

Year ended
January 31,

 

One month
ended
January 31,

 

Year ended
December 31,

 

 

 

2016

 

2015

 

2014

 

Research and development

 

$
256 

 

$
27 

 

 
228 

 

Sales and marketing

 

 
443 

 

 
40 

 

 
147 

 

General and administrative

 

 
515 

 

 
32 

 

 
818 

 

​

​

​  

​  

​

​  

​  

​

​  

​  

​

Total

 

$
1,214 

 

$
99 

 

$
1,193 

 

​

​

​  

​  

​

​  

​  

​

​  

​  

​

​

​

​  

​  

​

​  

​  

​

​  

​  

​

 

  
Black-Scholes option pricing model fair value assumptions

                                                                                                                                                                                    

 

 

Year ended
January 31,

 

One month
ended
January 31,

 

Year ended
December 31,

 

 

 

2016

 

2015

 

2014

 

Expected volatility

 

81.3% - 82.6%

 

 
82.1 

%

 
82.2 

%

Expected term in years

 

6.0

 

 
6.0 

 

 
6.0 

 

Risk-free interest rate

 

1.57% - 2.26%

 

 
1.56 

%

 
1.74 

%

Expected dividend yield

 

—%

 

 

—

%

 

—

%